Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide is not recommended during breastfeeding. Current UK guidance advises women to stop semaglutide before breastfeeding or to avoid breastfeeding while taking it, because it is not yet known whether the medicine passes into breast milk or what effect it might have on a nursing infant. This is the clear position of the NHS semaglutide patient information and the medicine's licensed summary of product characteristics. Semaglutide is a prescription-only medicine; any decision about starting, pausing or stopping treatment during this period must be made with your prescriber, GP or specialist, not independently.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is a question our prescribers hear most weeks from women who are either just finishing breastfeeding or wondering whether they can resume Wegovy sooner. The honest answer is that human data are genuinely limited. Animal studies suggest that semaglutide, a GLP-1 receptor agonist, can be detected in breast milk, but it is not established at what concentration, how consistently, or whether those amounts would be clinically meaningful for an infant. Because of that gap, the licensed position for semaglutide in the UK is precautionary: breastfeeding and semaglutide treatment should not run alongside each other. The NHS medicines information on semaglutide and the medicine's summary of product characteristics both reflect this clearly. No official UK body currently suggests it is safe to use while nursing, and that position is unlikely to change until adequately powered human studies are completed. If you are in any doubt, the right call is to pause treatment and speak to whoever manages your care.
If you are currently taking semaglutide and you are breastfeeding, or you are about to start breastfeeding, the practical guidance is to stop semaglutide first and let your prescriber know. Semaglutide has a half-life of approximately one week, so it takes several weeks to clear the body after the final dose; your prescriber can advise on the appropriate washout period in your specific situation. Do not simply stop without letting your clinical team know, partly because stopping abruptly can affect appetite and metabolic control and partly because your prescriber may want to review your wider health picture at that point. NHS England's guidance on weight-management medicines notes that these medicines are not recommended during breastfeeding, alongside similar cautions around pregnancy and trying to conceive. You can read more about the overlap between semaglutide treatment and pregnancy planning on our dedicated Wegovy and pregnancy page. Semaglutide is a prescription-only medicine, and changes of this kind are not something to navigate from the information on a packet alone.
Once breastfeeding has fully stopped, restarting semaglutide becomes a clinical conversation rather than an automatic step. Many women find that their weight and appetite shift significantly after weaning, and that context matters when deciding whether to restart, at what dose, and under what level of monitoring. If you previously held a prescription through a regulated online pharmacy, you would need a fresh clinical assessment before treatment resumes, at nume, every repeat order goes through clinical review regardless of your history with us. That review is completed the same working day by a GPhC-registered prescriber, not an automated system. If you want to understand the wider treatment landscape before that conversation, the Wegovy treatment overview covers how the medicine works, what the licensed eligibility criteria are, and what to expect from titration. The NHS England guidance on weight-management injections also covers the breastfeeding and conception exclusions clearly for anyone who wants a secondary reference.
Breastfeeding is one of several situations where the licensed guidance is straightforward: semaglutide should not be used. The same applies to pregnancy and to those who are actively trying to conceive; women who could become pregnant are advised to use reliable contraception during treatment. Semaglutide is not licensed for people under 18. Beyond these absolute positions, there are other health contexts where suitability is a more nuanced clinical judgement, for example, certain gastrointestinal conditions, a personal or family history of medullary thyroid carcinoma, and pancreatitis history all warrant careful prescriber assessment. If you have concerns about how semaglutide interacts with other aspects of your health, our general FAQs cover some of the most common questions, and you can explore specific topics such as semaglutide and alcohol or semaglutide and heart health in more detail, alongside questions about how Wegovy interacts with breastfeeding and whether semaglutide is effective for older patients. For this situation specifically, the safest step is always a direct conversation with a clinician who knows your full history. You can start that process through a free consultation with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.